
Opinion|Videos|December 17, 2024
Premature Treatment Discontinuation (Time to Response)
Author(s)Darren M. Brenner, MD, Amy Ladewski, PA-C
Thought leaders explore premature treatment discontinuation and some of the reasons leading to it, such as time to response and safety in regards to the use of prescription therapies for IBS-C and CIC.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves mRNA-1010 (mFLUSIVA) as First mRNA Flu Vaccine for Adults 50 and Older
2
FDA Reviews Clesrovimab for Second-Season RSV Prevention in High-Risk Children
3
ACOG's New Guidance on Diagnosing Endometriosis Without Surgery
4
FDA Approves Oveporexton, First Orexin Receptor Agonist for Narcolepsy Type 1
5
























































































































































